(MENAFN- Straits Research)
Market Overview
The Latin America Medical Cannabis Market size was valued at USD 2.16 billion in 2025 and is projected to grow from USD 2.38 billion in 2026 to reach USD 5.25 billion by 2034, growing at a CAGR of 10.37% during the forecast period 2026–2034.
Medical cannabis, also known as medical marijuana, is a herbal medication derived from Cannabis plants used to treat specific symptoms or diseases, such as cancer, chronic pain, and psychiatric disorders. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the main cannabinoids extracted from this plant that provide medicinal benefits.
It is anticipated that the advancement of medicinal cannabis will fuel the development of this industry over the coming years through clinical trials and judgments made by regulatory agencies in developed countries. In addition, it is anticipated that over the forecast period, the status of medicinal cannabis will improve because of clinical trials and decisions taken by regulatory agencies in developed countries. But the market is constrained by a dearth of knowledge about the advantages of medical marijuana and strict regulatory requirements.
Highlights
Dissolvable/Powders dominate the market by Product.
Cannabidiol dominates the market by Derivative.
Inhalation dominates the market by Route of Administration.
Pain Management dominates the market by Application.
Inflammatory Pain dominates the market in Pain Management.
Epilepsy dominates the market in Neurological Health Management.
Anxiety dominates the market by Mental Health Management
Hospital Pharmacy dominates the market by Distribution Channel
Download a Free Sample To learn more about this report,
Market Dynamics
Latin America Medical Cannabis Market Drivers:
Rising Occurrence of Chronic Diseases and Other Medical Conditions
In Latin America, the population is affected by several chronic diseases, including glaucoma, multiple sclerosis, epilepsy, spasticity brought on by multiple sclerosis or spinal cord injury, fibromyalgia, and chemotherapy-induced nausea and vomiting. Because there is strong evidence that cannabis is an effective treatment for many ailments, the demand for cannabis-based medications is rising along with the prevalence of these conditions.
Increasing Acceptance of Medical Cannabis
The acceptance of medical marijuana is rising gradually throughout the Latin American region. This change is ascribed to several things, including rising knowledge of cannabis' therapeutic potential, successful patient tales, and changing societal attitudes toward alternative medicine. The acceptance and demand for medical cannabis are anticipated to increase as more patients and healthcare professionals realize its effectiveness in treating chronic pain, epilepsy, and cancer-related symptoms.
Regulatory Changes
Chronic diseases like cancer, HIV/AIDS, multiple sclerosis, and chronic pain problems are becoming more common in the Latin American region. Medical marijuana has shown promise in easing the symptoms of various diseases, offering relief, and enhancing patients' quality of life. The demand for medical cannabis as an alternative or supplementary therapy is anticipated to soar in Latin America as chronic disease burdens rise.
Latin America Medical Cannabis Market Restraints:
Adverse Effects Associated with Cannabis
Cannabis has been shown to have positive health impacts, but it also has negative ones. Heavy or prolonged cannabis usage has been linked to addiction, altered brain development, decreased life satisfaction, cognitive impairment, and poor educational outcomes, according to a 2017 study published in the Pharmacy and Therapeutics journal. According to a study, dizziness was the non-serious side effect that participants exposed to cannabinoids reported occurring the most frequently (15.5% of the time). Chronic bronchitis and psychosis-related health issues are also more likely to develop in cannabis users over the long term. It is clear from the available data that cannabis' negative side effects can have a significant negative influence on market expansion.
Latin America Medical Cannabis Market Opportunities:
Stringent Government Policies Related to Cbd Oil
Chronic diseases like cancer, HIV/AIDS, multiple sclerosis, and chronic pain problems are becoming more common in Latin America. Medical marijuana has shown promise in easing the symptoms of various diseases, offering relief, and enhancing patients' quality of life. The demand for medical cannabis as an alternative or supplementary therapy is anticipated to soar in Latin America as chronic disease burdens rise.
Rising Awareness about the Benefits of Medical Cannabis
There is a growing awareness about the benefits of medical cannabis. People are becoming more aware of the potential of medical cannabis to treat a variety of conditions. This is leading to an increase in the demand for medical cannabis products.
Latin America Medical Cannabis Market Segmentation Analysis
By Product Type
The Latin America Medical Cannabis Market is segmented into Flowers, Concentrates, Topicals & Transdermal Formulations, Oils & Tinctures, and Other Product Types. Flowers include dried cannabis products used under regulated medical programs, while concentrates provide higher concentrations of cannabinoids for selected therapeutic applications. Topicals and transdermal formulations are designed for localized or systemic delivery through the skin, whereas oils and tinctures provide controlled administration and dosing flexibility. Oils & Tinctures represent an important product category due to their convenient administration and ability to provide consistent cannabinoid dosing, while increasing availability of regulated cannabis formulations is supporting demand across the region.
Growing acceptance of medical cannabis, increasing patient awareness, expansion of regulated medical cannabis programs, and improvements in extraction and formulation technologies are supporting product diversification across Latin America. Flowers continue to maintain demand in markets where their medical use is permitted, while concentrates are benefiting from advances in cannabinoid extraction and formulation. Topical and transdermal products are creating opportunities for localized therapeutic applications, while oils and tinctures are gaining attention because of their ease of use and flexible dosing. Continued regulatory development and increasing availability of pharmaceutical-grade products are expected to support further growth across product categories.
Request Customization to receive a tailored report.
By Application
The Latin America Medical Cannabis Market is segmented into Oncology, Chronic Pain Management, Mental Health Management, Neurological Disease Management, and Other Applications. Oncology applications include supportive management of symptoms associated with cancer and its treatment, while chronic pain management represents a major therapeutic area because of the increasing burden of persistent pain conditions. Mental Health Management includes selected applications related to conditions such as anxiety and depression, while Neurological Disease Management covers conditions such as epilepsy, multiple sclerosis, and other neurological disorders. Other applications include additional therapeutic areas where medical cannabis may be considered under applicable clinical and regulatory frameworks.
Chronic Pain Management represents a significant application area, supported by the prevalence of chronic pain and increasing interest in alternative treatment approaches. Oncology applications are also gaining importance because cannabis-based medicines may be used for selected treatment-related symptoms, while Neurological Disease Management is supported by increasing research and clinical interest in conditions such as epilepsy and multiple sclerosis. Mental Health Management is developing as awareness and research around cannabinoid-based therapies increase. Growing physician awareness, expanding clinical research, increasing patient acceptance, and the development of regulated prescribing frameworks are expected to support application growth across Latin America.
By Distribution Channel
The Latin America Medical Cannabis Market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies. Hospital pharmacies distribute medical cannabis products within healthcare institutions and are particularly important for physician-supervised treatment and patients receiving specialized care. Drug Stores & Retail Pharmacies provide access to eligible patients in markets where medical cannabis distribution through pharmacies is permitted, while Online Pharmacies provide digital ordering and delivery capabilities where legally authorized. Hospital pharmacies represent an important distribution channel due to the increasing integration of medical cannabis into regulated healthcare pathways and the need for appropriate dispensing and patient guidance.
Drug Stores & Retail Pharmacies are benefiting from expanding access to regulated medical cannabis and established pharmaceutical distribution networks, while Online Pharmacies are gaining opportunities from increasing digital healthcare adoption and demand for convenient prescription fulfillment. Hospital pharmacies continue to support clinically supervised treatment and specialized patient care, particularly in markets where medical cannabis is available through prescription-based programs. Regulatory developments, improving healthcare infrastructure, digitalization of pharmaceutical services, and increasing patient demand for convenient access are expected to support the expansion of distribution channels across Latin America.
Speak to an Analyst to discuss market opportunities.
Regional Analysis
The Latin America medical cannabis market is segmented by country into Argentina, Brazil, Chile, Colombia, and Mexico.
Nearly every nation in Latin America has legalized medical marijuana, and some forms of recreational marijuana use are no longer considered crimes in Argentina, Brazil, Chile, Colombia, and Mexico. Most of the time, it is based on the quantity in possession or being grown. The first country to enact legislation establishing a national legal market for medicinal and recreational cannabis was Uruguay in 2013. Mexico is committed to following a similar path in 2020, which the current administration supports.
In Latin America, Uruguay, Argentina, Brazil, Chile, Colombia, Mexico, Paraguay, and Chile all permit the use of cannabis for medical purposes. Ecuador's Criminal Code has undergone modification, which allows expanding access to cannabis for "therapeutic, palliative, or medicinal" uses. Caribbean nations are likewise reexamining their marijuana regulations. For instance, Jamaica changed its laws in 2015 to decriminalize possession, permit the growth of up to five plants, and permit their usage for therapeutic and religious purposes. A regulation allowing the medical use of cannabis products with less than 1% THC was passed in Mexico in June 2017. As a result, Latin America offers several options for indigenous startups to market their goods.
List of Key and Emerging Players in Latin America Medical Cannabis Market
Medmen Enterprises
Aurora Cannabis
Trulieve Cannabis Corp.
Green Thumb Industries
Aphria Inc.
Tilray
Acreage Holdings Inc
Cronos Group
Vireo Health International
Key Industry Developments
November 2025: Tilray Medical obtained a medical cannabis license in Panama through its joint venture with Solana Life Group, establishing a strategic platform to expand regulated medical cannabis distribution and patient access across Latin America.
May 2026: Bioxyne Limited, through its subsidiary Breathe Life Sciences (BLS), signed an expanded supply agreement with Remidose LATAM SRL to supply Dr Watson medicinal cannabis flower products to Costa Rica. The agreement represents the first international commercial supply of medicinal cannabis flower into Costa Rica's regulated market.
June 2026: Tilray Medical announced the commercial launch of its first medical cannabis product in Panama, introducing Tilray Oral Solution CBD100 through its joint venture with Solana Life Group. The launch expands access to pharmaceutical-grade cannabinoid medicines under Panama's regulated medical cannabis framework and strengthens Tilray's presence in Latin America.
July 2026: Tilray Medical expanded its distribution network in Panama by making Tilray Oral Solution CBD100 available through Farmacias Arrocha, one of the country's largest pharmacy chains. The commercialization initiative enhances patient access to prescription medical cannabis products and reinforces the company's regional expansion strategy.
Report Scope
Comments
No comment